Joel Beatty
Stock Analyst at Baird
(4.51)
# 254
Out of 5,067 analysts
200
Total ratings
49.07%
Success rate
29.69%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $177.48 | +17.76% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $69.50 | +79.86% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $15.11 | +25.74% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.59 | +95.26% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $42.35 | +58.21% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.52 | +138.10% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $38.23 | -76.46% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $23.39 | +32.54% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $20.53 | +16.90% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $911.00 | -25.36% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $18.54 | +56.42% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $80.11 | -17.61% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $149.43 | +8.41% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $28.26 | +45.08% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $10.70 | +49.53% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $10.56 | +51.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $170.27 | -57.13% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $23.49 | +36.23% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $59.05 | +27.01% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.70 | +311.76% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $55.32 | +17.50% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $34.12 | +111.02% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.35 | +17,677.78% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.15 | +293.01% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $17.28 | +44.68% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $18.39 | +52.26% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.51 | +959.60% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.87 | -33.16% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.56 | +2,729.58% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $42.88 | +35.26% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $34.74 | -30.92% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $6.21 | +189.86% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.07 | +189.86% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.84 | +379.45% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $437.97 | -60.04% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.80 | +191.67% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.23 | +492.59% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $77.45 | +0.71% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $13.75 | +627.27% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.33 | +634.84% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.81 | +11,711.02% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.15 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.47 | +131.84% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $3.13 | +38,238.66% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $11.50 | +65.22% | 3 | Nov 10, 2017 |
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $177.48
Upside: +17.76%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $69.50
Upside: +79.86%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $15.11
Upside: +25.74%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.59
Upside: +95.26%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $42.35
Upside: +58.21%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.52
Upside: +138.10%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $38.23
Upside: -76.46%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $23.39
Upside: +32.54%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $20.53
Upside: +16.90%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $911.00
Upside: -25.36%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $18.54
Upside: +56.42%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $80.11
Upside: -17.61%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $149.43
Upside: +8.41%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $28.26
Upside: +45.08%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $10.70
Upside: +49.53%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $10.56
Upside: +51.52%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $170.27
Upside: -57.13%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $23.49
Upside: +36.23%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $59.05
Upside: +27.01%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.70
Upside: +311.76%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $55.32
Upside: +17.50%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $34.12
Upside: +111.02%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.35
Upside: +17,677.78%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.15
Upside: +293.01%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $17.28
Upside: +44.68%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $18.39
Upside: +52.26%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.51
Upside: +959.60%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.87
Upside: -33.16%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.56
Upside: +2,729.58%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $42.88
Upside: +35.26%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $34.74
Upside: -30.92%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $6.21
Upside: +189.86%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.07
Upside: +189.86%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.84
Upside: +379.45%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $437.97
Upside: -60.04%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.80
Upside: +191.67%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.23
Upside: +492.59%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $77.45
Upside: +0.71%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $13.75
Upside: +627.27%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.33
Upside: +634.84%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.81
Upside: +11,711.02%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.15
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.47
Upside: +131.84%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $3.13
Upside: +38,238.66%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $11.50
Upside: +65.22%